Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib

This study investigated predictors of early response to baricitinib in 44 patients with severe alopecia areata. It found that early responders, who made up 34.1% of the cohort, were more likely to have a lower baseline Severity of Alopecia Tool (SALT) score, shorter disease duration, and elevated erythrocyte sedimentation rate (ESR) at baseline. The study suggests that these clinical and laboratory parameters can help identify patients who are most likely to benefit from baricitinib treatment, highlighting a therapeutic window of opportunity for those with lower disease burden and shorter disease duration.